Boston Scientific Goodwill and Intangible Assets 2010-2024 | BSX
Boston Scientific goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Boston Scientific goodwill and intangible assets for the quarter ending June 30, 2024 were $19.814B, a 0.47% increase year-over-year.
- Boston Scientific goodwill and intangible assets for 2023 were $20.39B, a 8.33% increase from 2022.
- Boston Scientific goodwill and intangible assets for 2022 were $18.822B, a 3.94% increase from 2021.
- Boston Scientific goodwill and intangible assets for 2021 were $18.109B, a 14.12% increase from 2020.
| Boston Scientific Annual Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2023 | $20,390 |
| 2022 | $18,822 |
| 2021 | $18,109 |
| 2020 | $15,868 |
| 2019 | $18,062 |
| 2018 | $14,283 |
| 2017 | $12,835 |
| 2016 | $12,561 |
| 2015 | $12,667 |
| 2014 | $11,504 |
| 2013 | $11,643 |
| 2012 | $12,262 |
| 2011 | $16,234 |
| 2010 | $16,529 |
| 2009 | $18,603 |
| Boston Scientific Quarterly Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2024-06-30 | $19,814 |
| 2024-03-31 | $20,200 |
| 2023-12-31 | $20,390 |
| 2023-09-30 | $19,457 |
| 2023-06-30 | $19,722 |
| 2023-03-31 | $19,329 |
| 2022-12-31 | $18,822 |
| 2022-09-30 | $18,910 |
| 2022-06-30 | $19,232 |
| 2022-03-31 | $19,530 |
| 2021-12-31 | $18,109 |
| 2021-09-30 | $18,047 |
| 2021-06-30 | $16,662 |
| 2021-03-31 | $16,859 |
| 2020-12-31 | $15,868 |
| 2020-09-30 | $16,934 |
| 2020-06-30 | $17,261 |
| 2020-03-31 | $17,491 |
| 2019-12-31 | $18,062 |
| 2019-09-30 | $18,089 |
| 2019-06-30 | $14,937 |
| 2019-03-31 | $14,627 |
| 2018-12-31 | $14,283 |
| 2018-09-30 | $13,885 |
| 2018-06-30 | $13,176 |
| 2018-03-31 | $12,697 |
| 2017-12-31 | $12,835 |
| 2017-09-30 | $12,665 |
| 2017-06-30 | $12,792 |
| 2017-03-31 | $12,423 |
| 2016-12-31 | $12,561 |
| 2016-09-30 | $12,336 |
| 2016-06-30 | $12,405 |
| 2016-03-31 | $12,539 |
| 2015-12-31 | $12,667 |
| 2015-09-30 | $12,696 |
| 2015-06-30 | $11,372 |
| 2015-03-31 | $11,395 |
| 2014-12-31 | $11,504 |
| 2014-09-30 | $11,633 |
| 2014-06-30 | $11,394 |
| 2014-03-31 | $11,499 |
| 2013-12-31 | $11,643 |
| 2013-09-30 | $11,489 |
| 2013-06-30 | $11,579 |
| 2013-03-31 | $11,729 |
| 2012-12-31 | $12,262 |
| 2012-09-30 | $11,878 |
| 2012-06-30 | $12,723 |
| 2012-03-31 | $16,144 |
| 2011-12-31 | $16,234 |
| 2011-09-30 | $16,333 |
| 2011-06-30 | $16,442 |
| 2011-03-31 | $16,554 |
| 2010-12-31 | $16,529 |
| 2010-09-30 | $16,883 |
| 2010-06-30 | $16,998 |
| 2010-03-31 | $17,097 |
| 2009-12-31 | $18,603 |
| 2009-09-30 | $19,287 |
| 2009-06-30 | $19,406 |
| 2009-03-31 | $19,539 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $122.743B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $195.617B | 25.27 |
| Stryker (SYK) | United States | $137.290B | 32.08 |
| Medtronic (MDT) | Ireland | $114.552B | 17.05 |
| EssilorLuxottica (ESLOY) | France | $108.842B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.651B | 35.57 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.030B | 0.00 |
| ResMed (RMD) | United States | $35.117B | 30.92 |
| Koninklijke Philips (PHG) | Netherlands | $30.774B | 23.39 |
| Terumo (TRUMY) | Japan | $28.517B | 40.27 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.039B | 13.87 |
| Baxter (BAX) | United States | $19.851B | 13.46 |
| Insulet (PODD) | United States | $16.269B | 68.45 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.605B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.247B | 30.63 |
| Demant (WILYY) | Denmark | $8.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.898B | 33.39 |
| Lantheus Holdings (LNTH) | United States | $7.454B | 17.89 |
| ICU Medical (ICUI) | United States | $4.261B | 40.67 |
| Haemonetics (HAE) | United States | $4.084B | 20.20 |
| TG Therapeutics (TGTX) | United States | $3.689B | 39.07 |
| Neogen (NEOG) | United States | $3.599B | 37.75 |
| Prestige Consumer Healthcare (PBH) | United States | $3.534B | 17.61 |
| GN Store Nord (GNNDY) | Denmark | $3.509B | 21.14 |
| Perrigo (PRGO) | Ireland | $3.499B | 11.06 |
| Envista Holdings (NVST) | United States | $3.398B | 18.13 |
| QuidelOrtho (QDEL) | United States | $3.063B | 19.30 |
| Agios Pharmaceuticals (AGIO) | United States | $2.595B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.226B | 37.36 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.124B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.061B | 54.92 |
| Warby Parker (WRBY) | United States | $1.614B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.497B | 10.81 |
| InMode (INMD) | Israel | $1.464B | 9.32 |
| AtriCure (ATRC) | United States | $1.372B | 0.00 |
| Owens & Minor (OMI) | United States | $1.247B | 9.63 |
| Verano Holdings (VRNOF) | United States | $1.184B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.123B | 0.00 |
| Evolus (EOLS) | United States | $1.006B | 0.00 |
| PetIQ (PETQ) | United States | $0.919B | 23.30 |
| Phibro Animal Health (PAHC) | United States | $0.894B | 18.55 |
| National Vision Holdings (EYE) | United States | $0.867B | 27.55 |
| Cresco Labs (CRLBF) | United States | $0.805B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 116.64 |
| Quanterix (QTRX) | United States | $0.489B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.488B | 14.72 |
| Jin Medical (ZJYL) | China | $0.439B | 0.00 |
| ZimVie (ZIMV) | United States | $0.435B | 40.41 |
| Valneva SE (VALN) | France | $0.432B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.402B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.389B | 0.00 |
| Cerus (CERS) | United States | $0.324B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.324B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.320B | 8.25 |
| Aurora Cannabis (ACB) | Canada | $0.319B | 0.00 |
| Biote (BTMD) | United States | $0.307B | 14.18 |
| Viemed Healthcare (VMD) | United States | $0.283B | 30.38 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| Zynex (ZYXI) | United States | $0.257B | 45.00 |
| Utah Medical Products (UTMD) | United States | $0.232B | 15.41 |
| Omeros (OMER) | United States | $0.227B | 0.00 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.194B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.163B | 67.33 |
| FitLife Brands (FTLF) | United States | $0.153B | 20.64 |
| Brainsway (BWAY) | Israel | $0.135B | 161.40 |
| TriSalus Life Sciences (TLSI) | United States | $0.130B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.121B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.114B | 0.00 |
| Veru (VERU) | United States | $0.113B | 0.00 |
| Fonar (FONR) | United States | $0.111B | 11.44 |
| Jushi Holdings (JUSHF) | United States | $0.104B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.101B | 24.80 |
| InterCure (INCR) | Israel | $0.087B | 14.62 |
| Zevia PBC (ZVIA) | United States | $0.083B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.082B | 0.00 |
| Modular Medical (MODD) | United States | $0.074B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.073B | 0.00 |
| Safety Shot (SHOT) | United States | $0.071B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.051B | 3.35 |
| Apyx Medical (APYX) | United States | $0.042B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.040B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.008B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.007B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 21.30 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |